This article contains some facts regarding TrimetazidineTrimetazidine is an effective and well tolerated anti-ischaemic agent which, in addition to providing symptom relief and functional improvement in patients with angina pectoris, has a cytoprotective action during ischaemia.
The drug is suitable for initial use as monotherapy in patients with angina pectoris and, because of its different mechanism of action, as adjunctive therapy in those with symptoms not sufficiently controlled by nitrates, beta-blockers or calcium antagonists.
The role of trimetazidine in other coronary conditions has yet to be clearly established.
Trimetazidine is a medicine used to prevent angina attacks, which are sudden pains to the chest, jaw and back brought on by physical effort, due to reduced blood flow to the heart. Angina is commonly associated with a narrowing of the blood vessels that supply the heart, called the coronary arteries.
Trimetazidine is a 'metabolic agent', a medicine which has an effect on metabolism (the process by which substances are broken down in the body). It is believed to protect against myocardial ischaemia (reduced blood supply to the heart muscle) by increasing the rate at which glucose is broken down.
Trimetazidine is also used to treat the symptoms of vertigo (a spinning sensation) and tinnitus (ringing sensation in the ears), and to treat reduced vision and visual field disturbances (unclear or disturbed vision) due to problems affecting the blood vessels.
Trimetazidine was reclassified since the beginning of 2015. It was only prohibited in-competition only until the end of 2014.
Trimetazidine was originally included in S6.b based upon the similarity of its chemical structure to some of the listed Stimulants.
It has been moved to the newly created sub-section S4.5.c as it is pharmacologically classified as a modulator of cardiac metabolism.
Sources: WADA, PubMed, European Medicines Agency